Patent SG-11201809221W-A (SG)
Title: Administration of berberine metabolites
Inventor: Lowery Ryan
IPC: A61K31/4375
Filed: 2017-04-19
Abstract: 60 14) 104104 4:500: mg 013.: 250 niF,,DH.BB 5tia . fag I3HBp 14S (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 26 October 2017 (26.10.2017) WIPO I PCT omit IIl mum o mo IIV Eno iflo oimIE (10) International Publication Number WO 2017/184789 Al (51) International Patent Classification: A61K 31/43 75 (2006.01) A61K 31/23 (2006.01) A61K 31/19 (2006.01) (21) International Application Number: PCT/US2017/028466 (22) International Filing Date: 19 April 2017 (19.04.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/324,794 19 April 2016 (19.04.2016) US 15/491,933 19 April 2017 (19.04.2017) US (71) Applicant: KETO PATENT GROUP, INC. [US/US]; 901 Sam Rayburn Higway, Melissa, TX 75454 (US). (72) Inventors: LOWERY, Ryan; 3517 Harken Circle, Tam- pa, FL 33607 (US). WILSON, Jacob; 110 S Matanzas Ave., Tampa, FL 33609 (US). WELLS, Shawn; 2504 Lincolnshire Lane, Lewisville, TX 75056 (US). UNDER- WOOD, Brian; 901 Sam Rayburn Highway, Melissa, TX 75454 (US). HARDING, Chistopher, N.; 2155 S. Ocean Blvd #16, Delray Beach, FL (US). LACORE, Terry; 901 Sam Rayburn Highway, Medlissa, TX 75454 (US). (74) Agent: DAHM, Elizabeth, Philip; Ferguson Braswell Fraser Kubasta PC, 2500 Dallas Parkway, Suite 600, Plano, TX 75093 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (54) Title: ADMINISTRATION OF BERBERINE METABOLITES Figure 1 (57) : In various implementations, berberine metabolites, such as dihydroberberine and/or tetrahydroberberine, may be ad- ministered to manage blood glucose levels, increase ketone levels (e.g., blood concentration of ketones), and/or for therapeutic purposes in humans. The administration of a pharmaceutically effective amount of berberine metabolites, such as dihydroberberine, may reduce fasting blood glucose levels, improve glucose tolerance, and/or improve blood ketone response. In some implementations, berberine metabolites may be administered with one or more other compounds. [Continued on next page] WO 2017/184789 Al MIDEDIMOMOIDEIROIDEMOMOHOHOMEHOMEMOIMIE TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) Published: — with international search report (Art. 21(3))